Clinical trial

Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

NCT06798558

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Lu-17-PSMA-617 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-03-05

PhasePHASE2

Conditions

Prostate Adenocarcinomaverified · MONDO: prostate adenocarcinoma

Interventions

Lu-17-PSMA-617DRUG

Sponsors & collaborators

Hackensack Meridian Healthlead sponsor

Lombardi Comprehensive Cancer Centercollaborator

Novartiscollaborator

Mapped research locations

Washington D.C.District of Columbia, United States2 HackensackNew Jersey, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06798558 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.